References

Efficacy figures shown on this site describe outcomes of the tirzepatide molecule in clinical trials, not StaveMD patient results. Individual results vary.

1. SURMOUNT-1 (ClinicalTrials.gov)

   A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1). ClinicalTrials.gov Identifier NCT04184622.

   Supports: ≈20.9% mean body-weight reduction and up to ~52 lbs average lost at the 15 mg dose over 72 weeks; tirzepatide as a dual GIP + GLP-1 receptor agonist.

   https://clinicaltrials.gov/study/NCT04184622 (accessed 2026-07-06)

2. SURMOUNT-1 (NEJM)

   Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216.

   Supports: Peer-reviewed publication of the SURMOUNT-1 results underlying the 20.9% / 52 lbs / 72-week efficacy figures.

   https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 (accessed 2026-07-06)